ABVC: ABVC BioPharma, Inc. Stock

by  •  • Comments Off on ABVC: ABVC BioPharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 19.86
Enterprise Value ($M) 23.90
Book Value ($M) 7.96
Book Value / Share 0.53
Price / Book 2.50
NCAV ($M) -5.45
NCAV / Share -0.36
Price / NCAV -3.64

Profitability (mra)
Return on Invested Capital (ROIC) -0.29
Return on Assets (ROA) -0.20
Return on Equity (ROE) -0.39

Liquidity (mrq)
Quick Ratio 0.22
Current Ratio 0.22

Balance Sheet (mrq) ($M)
Current Assets 1.47
Assets 14.88
Liabilities 6.92
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.51
Operating Income -4.71
Net Income -4.90
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -1.81
Cash from Investing 0.00
Cash from Financing 1.98

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Lind Global Fund II LP 9.90 15.22

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-30 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO
2025-04-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-17 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-08 67,308 316,992 21.23
2025-05-07 81,085 297,135 27.29
2025-05-06 40,316 104,570 38.55
2025-05-05 56,553 176,697 32.01

(click for more detail)

Similar Companies
ABEO – Abeona Therapeutics Inc. ACB – Aurora Cannabis Inc.
ACHV – Achieve Life Sciences, Inc.


Financial data and stock pages provided by
Fintel.io